Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy

Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade therapy has become a game-changing therapeutic approach revolutionizing the treatment setting of human malignancies, such as renal cell carcinoma (RCC). Despite the remarkable clinical activity of anti-PD-1 or anti-PD-L1 monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales: Jahangir, Mohammadsaleh, Yazdani, Omid, Kahrizi, Mohammad Saeed, Soltanzadeh, Sara, Javididashtbayaz, Hamidreza, Mivefroshan, Azam, Ilkhani, Saba, Esbati, Romina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743549/
https://www.ncbi.nlm.nih.gov/pubmed/36510217
http://dx.doi.org/10.1186/s12935-022-02816-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743549/
https://www.ncbi.nlm.nih.gov/pubmed/36510217
http://dx.doi.org/10.1186/s12935-022-02816-3

Ejemplares similares